REHOVOT, Israel and BRIDGEWATER, N.J., March 3, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dov Tamarkin, Chief Executive Officer of Foamix Pharmaceuticals, will provide a corporate overview and business update at the Barclays Global Healthcare Conference.
|Title:||Barclays Global Healthcare Conference|
|Date:||Tuesday, March 10, 2015|
|Location:||Lowes Miami Beach Hotel, Miami, FL|
About Foamix Pharmaceuticals
We are a clinical-stage specialty pharmaceutical company focused on developing and commercializing our proprietary minocycline foam for the treatment of acne and other skin conditions. Our lead product candidate, FMX101 for moderate-to-severe acne, is a novel topical foam formulation of the antibiotic minocycline. We also have early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.
CONTACT: U.S. Investor Relations Andrew McDonald LifeSci Advisors, LLC 646-597-6987 email@example.com